Revolutionary Blood Test Predicts Breast Cancer Recurrence with 100% Accuracy
Learn about the groundbreaking new blood test that can predict breast cancer recurrence with 100% accuracy, offering hope for early detection and treatment. Stay informed on the latest healthcare advancements to protect yourself and your loved ones from the risks of breast cancer.
Groundbreaking Cancer Research Developments
Discover 11 groundbreaking developments in cancer research, including personalized cancer vaccines, early-stage cancer detection tests, targeted therapies, liquid biopsies, immunotherapy, artificial intelligence, genomic sequencing, nanotechnology, cancer immunogenomics, minimal residual disease monitoring, and collaborative research initiatives. These innovative approaches aim to revolutionize cancer care and improve outcomes for patients worldwide.
DELFI Diagnostics Announces Availability of Fragmentome-Based Cancer Monitoring Assay and Collaboration with Immunocore Holdings plc
DELFI Diagnostics, Inc. has announced the availability of the company’s fragmentome-based research use only (RUO) cancer monitoring assay, offering a highly sensitive, inexpensive means of noninvasive measurement of tumor burden and assessing treatment response and resistance in patients with advanced cancer. The company has also revealed a new research collaboration with Immunocore Holdings plc, focusing on exploring the use of the DELFI-TF cancer monitoring assay as an early predictor of benefit from treatment with ImmTAC-based therapies. DELFI Diagnostics is developing next-generation, blood-based tests that are accurate, accessible and deliver a new way to help detect cancer.